​

Castle Biosciences Ownership | Who Owns Castle Biosciences?

OverviewForecastRevenueFinancialsChartTranscripts

Castle Biosciences Ownership Summary

Castle Biosciences is owned by 78.05% institutional investors, 2.90% insiders, and 19.05% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.40% of CSTL shares. Bellevue Healthcare Ord is the top mutual fund, with 4.32% of its assets in Castle Biosciences shares.

CSTL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCastle Biosciences78.05%2.90%19.05%
SectorHealthcare Stocks 232.64%10.66%-143.30%
IndustryDiagnostics & Research Stocks35.92%10.61%53.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de3.11M12.40%$120.79M
Blackrock3.04M11.08%$66.29M
Vanguard group2.20M8.78%$85.57M
Principal financial group1.81M7.22%$70.32M
Portolan capital management1.52M5.24%$34.50M
Dimensional fund advisors lp1.14M4.57%$44.49M
Geode capital management714.91K2.85%$27.81M
Braidwell lp822.74K2.85%$18.73M
State street724.08K2.50%$16.49M
Aigh capital management624.72K2.49%$24.30M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aigh capital management624.72K5.88%$24.30M
Birchview capital, lp110.60K1.90%$2.52M
Portolan capital management1.52M1.87%$34.50M
Parkman healthcare partners475.57K1.13%$10.83M
Perkins capital management28.05K0.87%$1.09M
Braidwell lp822.74K0.56%$18.73M
Palisade capital management, lp638.66K0.40%$14.54M
Green alpha advisors10.24K0.36%$398.18K
Eam investors74.14K0.32%$2.88M
Kornitzer capital management inc /ks267.73K0.22%$10.41M

Top Buyers

HolderShares% AssetsChange
Blackrock3.04M0.00%449.29K
Millennium management548.81K0.01%408.27K
Summit partners public asset management400.00K0.19%400.00K
Point72 asset management336.96K0.01%336.96K
Jane street group168.65K0.00%145.76K

Top Sellers

HolderShares% AssetsChange
Park west asset management---556.49K
Nuveen524.68K0.01%-432.40K
Wellington management group llp---407.21K
Dimensional fund advisors lp1.14M0.01%-330.29K
Bellevue group---301.10K

New Positions

HolderShares% AssetsChangeValue
Summit partners public asset management400.00K0.19%400.00K$9.11M
D. e. shaw90.56K0.00%90.56K$2.41M
Eam investors74.14K0.32%74.14K$2.88M
Summittx capital45.00K0.04%45.00K$1.02M
Aqr capital management21.11K0.00%21.11K$562.72K

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
National bank of canada /fi/-1.00
Nelson, van denburg & campbell wealth management group-1.00
Stephens consulting-2.00
Colonial trust advisors-6.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025157-10.80%19,552,468-26.63%780.92%80-18.37%575.56%
Sep 30, 202517112.50%26,525,363-0.04%911.09%939.41%5420.00%
Jun 30, 2025151-17.03%26,530,4542.55%911.12%85-19.81%44-18.52%
Mar 31, 2025178-13.17%25,557,223-3.26%890.99%105-2.78%53-19.70%
Dec 31, 20242023.59%26,322,0332.20%941.10%106-11.67%6538.30%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Bellevue Healthcare Ord1.20M4.32%1.20M
Vanguard US Total Market Shares ETF829.40K2.96%-
Strategic Advisers U.S. Total Stock842.47K2.89%-
Principal U.S. Small Cap Select Equity834.44K2.86%797.24K
Principal U.S. Small Cap Equity834.44K2.86%4.50K
Vanguard Total Stock Mkt Idx Inv823.96K2.82%-
Principal SmallCap R5809.74K2.77%784.74K
Strategic Advisers U.S. Total Stock{mg}693.06K2.47%-
Wasatch Small Cap Growth Investor675.19K2.41%-14.34K
Strategic Advisers Small-Mid Cap665.91K2.40%62.85K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 18, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$16.50K
Mar 17, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$483.59K
Mar 13, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$336.00K
Mar 16, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$453.05K
Mar 16, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$3.36K

Insider Transactions Trends

DateBuySell
2026 Q1-22
2025 Q4-26
2025 Q3-7
2025 Q2-20
2025 Q1-61

CSTL Ownership FAQ

Who Owns Castle Biosciences?

Castle Biosciences shareholders are primarily institutional investors at 78.05%, followed by 2.90% insiders and 19.05% retail investors. The average institutional ownership in Castle Biosciences's industry, Diagnostics & Research Stocks, is 35.92%, which Castle Biosciences exceeds.

Who owns the most shares of Castle Biosciences?

Castle Biosciences’s largest shareholders are Blackrock funding, inc. /de (3.11M shares, 12.40%), Blackrock (3.04M shares, 11.08%), and Vanguard group (2.2M shares, 8.78%). Together, they hold 32.26% of Castle Biosciences’s total shares outstanding.

Does Blackrock own Castle Biosciences?

Yes, BlackRock owns 11.08% of Castle Biosciences, totaling 3.04M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 66.29M$. In the last quarter, BlackRock increased its holdings by 449.29K shares, a 17.31% change.

Who is Castle Biosciences’s biggest shareholder by percentage of total assets invested?

Aigh capital management is Castle Biosciences’s biggest shareholder by percentage of total assets invested, with 5.88% of its assets in 624.72K Castle Biosciences shares, valued at 24.3M$.

Who is the top mutual fund holder of Castle Biosciences shares?

Bellevue Healthcare Ord is the top mutual fund holder of Castle Biosciences shares, with 4.32% of its total shares outstanding invested in 1.2M Castle Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools